Literature DB >> 9864235

Partial protection against Plasmodium vivax blood-stage infection in Saimiri monkeys by immunization with a recombinant C-terminal fragment of merozoite surface protein 1 in block copolymer adjuvant.

C Yang1, W E Collins, J S Sullivan, D C Kaslow, L Xiao, A A Lal.   

Abstract

Merozoite surface protein 1 is a candidate for blood-stage vaccines against malaria parasites. We report here an immunization study of Saimiri monkeys with a yeast-expressed recombinant protein containing the C terminus of Plasmodium vivax merozoite surface protein 1 and two T-helper epitopes of tetanus toxin (yP2P30Pv20019), formulated in aluminum hydroxide (alum) and block copolymer P1005. Monkeys immunized three times with yP2P30Pv20019 in block copolymer P1005 had significantly higher prechallenge titers of immunoglobulin G (IgG) antibodies against the immunogen and asexual blood-stage parasites than those immunized with yP2P30Pv20019 in alum, antigen alone, or phosphate-buffered saline (PBS) (P < 0.05). Their peripheral blood mononuclear cell proliferative responses to immunogen stimulation 4 weeks after the second immunization were also significantly higher than those from the PBS control group (P < 0.05). Upon challenge with 100,000 asexual blood-stage parasites 5 weeks after the last immunization, monkeys immunized with yP2P30Pv20019 in block copolymer P1005 had prepatent periods longer than those for the control alone group (P > 0.05). Three of the five animals in this group also had low parasitemia (peak parasitemia, </=20 parasites/microliter of blood). Partially protected monkeys had significantly higher levels of prechallenge antibodies against the immunogen than those unprotected (P < 0.05). There was also a positive correlation between the prepatent period and titers of IgG antibodies against the immunogen and asexual blood-stage parasites and a negative correlation between accumulated parasitemia and titers of IgG antibodies against the immunogen (P < 0.05). These results indicate that when combined with block copolymer and potent T-helper epitopes, the yeast-expressed P2P30Pv20019 recombinant protein may offer some protection against malaria.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9864235      PMCID: PMC96316     

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  Mapping of the region predominantly recognized by antibodies to the Plasmodium falciparum merozoite surface antigen MSA 1.

Authors:  J A Cooper; L T Cooper; A J Saul
Journal:  Mol Biochem Parasitol       Date:  1992-04       Impact factor: 1.759

2.  Influence of adjuvants on the antibody specificity to the Plasmodium falciparum major merozoite surface protein, gp195.

Authors:  G S Hui; S P Chang; H Gibson; A Hashimoto; C Hashiro; P J Barr; S Kotani
Journal:  J Immunol       Date:  1991-12-01       Impact factor: 5.422

3.  Adjuvant activity of non-ionic block copolymers. V. Modulation of antibody isotype by lipopolysaccharides, lipid A and precursors.

Authors:  K Takayama; M Olsen; P Datta; R L Hunter
Journal:  Vaccine       Date:  1991-04       Impact factor: 3.641

4.  A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice.

Authors:  T M Daly; C A Long
Journal:  Infect Immun       Date:  1993-06       Impact factor: 3.441

5.  Use of human universally antigenic tetanus toxin T cell epitopes as carriers for human vaccination.

Authors:  D Valmori; A Pessi; E Bianchi; G Corradin
Journal:  J Immunol       Date:  1992-07-15       Impact factor: 5.422

6.  Structure and expression of the gene for Pv200, a major blood-stage surface antigen of Plasmodium vivax.

Authors:  H L Gibson; J E Tucker; D C Kaslow; A U Krettli; W E Collins; M C Kiefer; I C Bathurst; P J Barr
Journal:  Mol Biochem Parasitol       Date:  1992-02       Impact factor: 1.759

7.  Role of adjuvants in the modulation of antibody isotype, specificity, and induction of protection by whole blood-stage Plasmodium yoelii vaccines.

Authors:  T L ten Hagen; A J Sulzer; M R Kidd; A A Lal; R L Hunter
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

8.  Immunogenicity of Streptococcus pneumoniae type 14 capsular polysaccharide: influence of carriers and adjuvants on isotype distribution.

Authors:  J H van de Wijgert; A F Verheul; H Snippe; I J Check; R L Hunter
Journal:  Infect Immun       Date:  1991-08       Impact factor: 3.441

9.  Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains.

Authors:  M J Blackman; I T Ling; S C Nicholls; A A Holder
Journal:  Mol Biochem Parasitol       Date:  1991-11       Impact factor: 1.759

10.  Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge.

Authors:  L Rénia; I T Ling; M Marussig; F Miltgen; A A Holder; D Mazier
Journal:  Infect Immun       Date:  1997-11       Impact factor: 3.441

View more
  17 in total

1.  Merozoite surface protein 1 of Plasmodium vivax induces a protective response against Plasmodium cynomolgi challenge in rhesus monkeys.

Authors:  Sheetij Dutta; Deep C Kaushal; Lisa A Ware; Sunil K Puri; Nuzhat A Kaushal; Atul Narula; D S Upadhyaya; David E Lanar
Journal:  Infect Immun       Date:  2005-09       Impact factor: 3.441

2.  A comparative study of the genetic diversity of the 42kDa fragment of the merozoite surface protein 1 in Plasmodium falciparum and P. vivax.

Authors:  M Andreina Pacheco; Amanda C Poe; William E Collins; Altaf A Lal; Kazuyuki Tanabe; Simon K Kariuki; Venkatachalam Udhayakumar; Ananias A Escalante
Journal:  Infect Genet Evol       Date:  2006-09-28       Impact factor: 3.342

3.  A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies.

Authors:  I S Soares; J W Barnwell; M U Ferreira; M Gomes Da Cunha; J P Laurino; B A Castilho; M M Rodrigues
Journal:  Mol Med       Date:  1999-07       Impact factor: 6.354

4.  Purification, characterization, and immunogenicity of a disulfide cross-linked Plasmodium vivax vaccine candidate antigen, merozoite surface protein 1, expressed in Escherichia coli.

Authors:  S Dutta; L A Ware; A Barbosa; C F Ockenhouse; D E Lanar
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

5.  Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli.

Authors:  Suraksha Sachdeva; Gul Ahmad; Pawan Malhotra; Paushali Mukherjee; V S Chauhan
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 6.  Finding the sweet spots of inhibition: understanding the targets of a functional antibody against Plasmodium vivax Duffy binding protein.

Authors:  Francis B Ntumngia; Christopher L King; John H Adams
Journal:  Int J Parasitol       Date:  2012-10-12       Impact factor: 3.981

7.  Duffy Blood Group System and the malaria adaptation process in humans.

Authors:  Gledson Barbosa de Carvalho; Glauber Barbosa de Carvalho
Journal:  Rev Bras Hematol Hemoter       Date:  2011

8.  Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

Authors:  Balwan Singh; Monica Cabrera-Mora; Jianlin Jiang; Mary Galinski; Alberto Moreno
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

9.  Antigenic polymorphism and naturally acquired antibodies to Plasmodium vivax merozoite surface protein 1 in rural Amazonians.

Authors:  Melissa S Bastos; Mônica da Silva-Nunes; Rosely S Malafronte; Erika Hellena E Hoffmann; Gerhard Wunderlich; Sandra L Moraes; Marcelo U Ferreira
Journal:  Clin Vaccine Immunol       Date:  2007-08-15

Review 10.  Plasmodium vivax: who cares?

Authors:  Mary R Galinski; John W Barnwell
Journal:  Malar J       Date:  2008-12-11       Impact factor: 2.979

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.